SCM
Sio Capital Management Portfolio holdings
AUM
$395M
1-Year Est. Return
196.27%
1 Year Est. Return
+196.27%
AUM
$395M
AUM Growth
+$146M
(+59%)
Holding
66
Top Buys
| 1 | +$38.9M | |
| 2 | +$20.2M | |
| 3 | +$17.7M | |
| 4 |
Henry Schein
HSIC
|
+$14.5M |
| 5 |
Kenvue
KVUE
|
+$13.7M |
Top Sells
| 1 | +$19.5M | |
| 2 | +$14.5M | |
| 3 | +$12.7M | |
| 4 |
Annexon
ANNX
|
+$9.83M |
| 5 |
SEPN
Septerna Inc
SEPN
|
+$7.43M |
Sector Composition
| 1 | Healthcare | 83.63% |
| 2 | Industrials | 12.89% |
| 3 | Consumer Staples | 3.47% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
51
Humacyte Inc Warrant
HUMAW
$18.8M
| $12.2K | ﹤0.01% |
49,998
|
|
||
52
Embecta
EMBC
$713M
| – | – |
-31,169
|
|
||
53
Enanta Pharmaceuticals
ENTA
$408M
| – | – |
-178,774
|
|
||
54
Globus Medical
GMED
$12.1B
| – | – |
-245,570
|
|
||
55
Idexx Laboratories
IDXX
$58.5B
| – | – |
0
|
|
||
56
INmune Bio
INMB
$42.3M
| – | – |
0
|
|
||
57
Merus
MRUS
$7.28B
| – | – |
-62,719
|
|
||
58
Neurocrine Biosciences
NBIX
$15.1B
| – | – |
-100,725
|
|
||
59
Travere Therapeutics
TVTX
$3.13B
| – | – |
-122,210
|
|
||
60
Alector
ALEC
$134M
| – | – |
-845,531
|
|
||
|
61
Annexon
ANNX
$611M
| – | – |
-4,095,764
|
|
||
62
Artivion
AORT
$2.15B
| – | – |
-158,736
|
|
||
63
Astria Therapeutics
ATXS
$720M
| – | – |
-318,256
|
|
||
64
Avanos Medical
AVNS
$542M
| – | – |
-288,849
|
|
||
|
ATYR
65
aTyr Pharma
ATYR
$74.2M
| – | – |
0
|
|
||
|
MBX
66
MBX Biosciences
MBX
$1.48B
| – | – |
-241,000
|
|